Moberg Pharma ABFRA:MB8 +2.28%59 Gross Margin % is 66.08% as of Mar. 2026, which is 10% below its 10-year median of 73.05. GuruFocus rates FRA:MB8 with a GF Score™ of 59/100 and a GF Value™ of €1.09. The stock has 1 warning sign investors should review. Among 938 Drug Manufacturers companies, Moberg Pharma AB ranks better than 64.39% on this metric.
The historical rank and industry rank for Moberg Pharma AB's Gross Margin % or its related term are showing as below:
FRA:MB8'
s Gross Margin % Range Over the Past 10 Years
Min: 57.38 Med: 73.05 Max: 75.49
Current: 57.38
During the past 13 years, the highestGross Margin % of Moberg Pharma AB was 75.49%. The lowest was 57.38%. And the median was 73.05%.
FRA:MB8's Gross Margin % is ranked better than 64.39% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.44
vs FRA:MB8: 57.38
Moberg Pharma AB had a gross margin of 66.08% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Moberg Pharma AB was 0.00% per year.
Moberg Pharma AB (FRA:MB8) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Moberg Pharma AB had a gross margin of 66.08% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Moberg Pharma AB Gross Margin % Related Terms
Moberg Pharma AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for Moberg Pharma AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moberg Pharma AB Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Moberg Pharma AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Moberg Pharma AB (FRA:MB8) has a Gross Margin % of 66.08% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Moberg Pharma AB and its competitors. This is 10% below median its historical median of 73.05. Over the past decade, Moberg Pharma AB's Gross Margin % has ranged from 57.38 to 75.49. According to the industry distribution chart, Moberg Pharma AB ranks #334 out of 938 companies in the Drug Manufacturers industry, placing it in the top 35.6%.
Is Moberg Pharma AB's Gross Margin % too high?
Moberg Pharma AB's current Gross Margin % of 66.08% is 10% below median its 10-year median of 73.05. Over the past 10 years, this metric has ranged from a low of 57.38 to a high of 75.49. The Drug Manufacturers industry median Gross Margin % is 48.44. Moberg Pharma AB's value of 66.08% is 36.4% above this industry median. Based on the distribution chart, Moberg Pharma AB ranks #334 out of 938 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #334 out of 938 companies for Gross Margin %. This puts Moberg Pharma AB in the upper half of its industry. The industry median Gross Margin % is 48.44. Moberg Pharma AB's value of 66.08% is 36.4% above this benchmark. Historically, Moberg Pharma AB's own Gross Margin % has ranged from 57.38 to 75.49 over the past decade. While the company's 10-year median is 73.05 vs. the industry median of 48.44, Moberg Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moberg Pharma AB's current Gross Margin % of 66.08% is 36.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Moberg Pharma AB and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current Gross Margin % is 66.08%, which is 10% below median its own 10-year median of 73.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Gross Margin % of 66.08%. The stock's GF Value™ is €1.09, compared to a current price of €0.81 — trading 26% below its estimated fair value. The current Gross Margin % is 66.08%, which is 10% below median its 10-year median of 73.05 and 36.4% above the Drug Manufacturers industry median of 48.44. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Gross Margin % is 66.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?
Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued.
The current stock price of €0.81 is trading 26% below its estimated GF Value™ of €1.09.
Key valuation signals for FRA:MB8:
Gross Margin %: 66.08% (10% below median its 10-year median of 73.05)
GF Value™: €1.09 vs. price of €0.81 (26% below fair value)
Industry Position: 36.4% above the Drug Manufacturers median (#334 of 938)
No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score
Get the complete analysis for FRA:MB8
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MB8 has been successfully added to your 
